Matthew K. Fust's Insider Trades & SAST Disclosures
Matthew K. Fust's most recent trade in Ultragenyx Pharmaceutical Inc. was a trade of 10,787 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on May 15, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Matthew K. Fust.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Ultragenyx Pharmaceutical ... | Matthew K. Fust | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2025 | 10,787 | 10,787 | - | - | Stock Option (Right to Buy) | |
| Ultragenyx Pharmaceutical ... | Matthew K. Fust | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2025 | 5,740 | 25,945 (0%) | 0% | 0 | Common Stock | |
| Neumora Therapeutics Inc. | Matthew K. Fust | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Feb 2025 | 85,586 | 0 | - | - | Stock Option (Right to Buy) | |
| Neumora Therapeutics Inc. | Matthew K. Fust | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 85,586 | 85,586 | - | - | Stock Option (Right to Buy) | |
| Neumora Therapeutics Inc. | Matthew K. Fust | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 28,571 | 28,571 | - | - | Stock Option (Right to Buy) | |
| Neumora Therapeutics Inc. | Matthew K. Fust | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Feb 2025 | 28,571 | 0 | - | - | Stock Option (Right to Buy) | |
| Neumora Therapeutics Inc. | Matthew K. Fust | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Feb 2025 | 27,802 | 0 | - | - | Stock Option (Right to Buy) | |
| Neumora Therapeutics Inc. | Matthew K. Fust | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 27,802 | 27,802 | - | - | Stock Option (Right to Buy) | |
| Neumora Therapeutics Inc. | Matthew K. Fust | Director | Sale of securities on an exchange or to another person at price $ 17.03 per share. | 17 Oct 2024 | 14,049 | 20,100 | - | 17.0 | 239,319 | Common Stock |
| Neumora Therapeutics Inc. | Matthew K. Fust | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Oct 2024 | 7,844 | 85,586 | - | - | Stock Option (Right to Buy) | |
| Neumora Therapeutics Inc. | Matthew K. Fust | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.52 per share. | 17 Oct 2024 | 7,844 | 34,149 | - | 2.5 | 19,767 | Common Stock |
| Neumora Therapeutics Inc. | Matthew K. Fust | Director | Sale of securities on an exchange or to another person at price $ 17.01 per share. | 17 Oct 2024 | 7,739 | 20,100 | - | 17.0 | 131,643 | Common Stock |
| Neumora Therapeutics Inc. | Matthew K. Fust | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Oct 2024 | 6,205 | 0 | - | - | Stock Option (Right to Buy) | |
| Neumora Therapeutics Inc. | Matthew K. Fust | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.79 per share. | 17 Oct 2024 | 6,205 | 26,305 | - | 8.8 | 54,542 | Common Stock |
| Neumora Therapeutics Inc. | Matthew K. Fust | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.32 per share. | 17 Oct 2024 | 3,783 | 23,883 | - | 8.3 | 31,475 | Common Stock |
| Neumora Therapeutics Inc. | Matthew K. Fust | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Oct 2024 | 3,783 | 0 | - | - | Stock Option (Right to Buy) | |
| Neumora Therapeutics Inc. | Matthew K. Fust | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Oct 2024 | 2,156 | 93,430 | - | - | Stock Option (Right to Buy) | |
| Neumora Therapeutics Inc. | Matthew K. Fust | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.52 per share. | 17 Oct 2024 | 2,156 | 27,839 | - | 2.5 | 5,433 | Common Stock |
| Neumora Therapeutics Inc. | Matthew K. Fust | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Oct 2024 | 1,800 | 6,205 | - | - | Stock Option (Right to Buy) | |
| Neumora Therapeutics Inc. | Matthew K. Fust | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.79 per share. | 17 Oct 2024 | 1,800 | 25,683 | - | 8.8 | 15,822 | Common Stock |
| Ultragenyx Pharmaceutical ... | Matthew K. Fust | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2024 | 9,900 | 9,900 | - | - | Stock Option (Right to Buy) | |
| Ultragenyx Pharmaceutical ... | Matthew K. Fust | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2024 | 5,345 | 20,205 (0%) | 0% | 0 | Common Stock | |
| Neumora Therapeutics Inc. | Matthew K. Fust | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 28,571 | 28,571 | - | - | Stock Option (Right to Buy) | |
| Neumora Therapeutics Inc. | Matthew K. Fust | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 20,100 | 20,100 | - | 0 | Common Stock | |
| Crinetics Pharmaceuticals Inc | Matthew K. Fust | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2024 | 12,500 | 12,500 | - | - | Stock Option (right to buy) | |
| Crinetics Pharmaceuticals Inc | Matthew K. Fust | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2024 | 3,400 | 21,936 (0%) | 0% | 0 | Common Stock | |
| Atara Biotherapeutics Inc | Matthew K. Fust | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2024 | 150,000 | 259,000 (0%) | 0% | 0 | Common Stock | |
| Crinetics Pharmaceuticals Inc | Matthew K. Fust | Director | Sale of securities on an exchange or to another person at price $ 45.50 per share. | 20 Mar 2024 | 17,500 | 18,536 (0%) | 0% | 45.5 | 796,250 | Common Stock |
| Crinetics Pharmaceuticals Inc | Matthew K. Fust | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.29 per share. | 20 Mar 2024 | 17,500 | 36,036 (0%) | 0% | 18.3 | 320,075 | Common Stock |
| Crinetics Pharmaceuticals Inc | Matthew K. Fust | Director | Sale of securities on an exchange or to another person at price $ 43.58 per share. | 20 Mar 2024 | 17,500 | 18,536 (0%) | 0% | 43.6 | 762,650 | Common Stock |
| Crinetics Pharmaceuticals Inc | Matthew K. Fust | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 20.23 per share. | 20 Mar 2024 | 17,500 | 36,036 (0%) | 0% | 20.2 | 354,025 | Common Stock |
| Crinetics Pharmaceuticals Inc | Matthew K. Fust | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Mar 2024 | 17,500 | 0 | - | - | Stock Option (right to buy) | |
| Crinetics Pharmaceuticals Inc | Matthew K. Fust | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Mar 2024 | 17,500 | 0 | - | - | Stock Option (right to buy) | |
| Crinetics Pharmaceuticals Inc | Matthew K. Fust | Director | Sale of securities on an exchange or to another person at price $ 43.57 per share. | 20 Mar 2024 | 12,500 | 18,536 (0%) | 0% | 43.6 | 544,625 | Common Stock |
| Crinetics Pharmaceuticals Inc | Matthew K. Fust | Director | Sale of securities on an exchange or to another person at price $ 43.57 per share. | 20 Mar 2024 | 12,500 | 18,536 (0%) | 0% | 43.6 | 544,625 | Common Stock |
| Crinetics Pharmaceuticals Inc | Matthew K. Fust | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 23.23 per share. | 20 Mar 2024 | 12,500 | 31,036 (0%) | 0% | 23.2 | 290,375 | Common Stock |
| Crinetics Pharmaceuticals Inc | Matthew K. Fust | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 23.24 per share. | 20 Mar 2024 | 12,500 | 31,036 (0%) | 0% | 23.2 | 290,500 | Common Stock |
| Crinetics Pharmaceuticals Inc | Matthew K. Fust | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Mar 2024 | 12,500 | 0 | - | - | Stock Option (right to buy) | |
| Crinetics Pharmaceuticals Inc | Matthew K. Fust | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Mar 2024 | 12,500 | 0 | - | - | Stock Option (right to buy) | |
| Ultragenyx Pharmaceutical ... | Matthew K. Fust | Director | Sale of securities on an exchange or to another person at price $ 50.88 per share. | 07 Mar 2024 | 7,500 | 14,860 (0%) | 0% | 50.9 | 381,600 | Common Stock |
| Ultragenyx Pharmaceutical ... | Matthew K. Fust | Director | Sale of securities on an exchange or to another person at price $ 50.89 per share. | 07 Mar 2024 | 2,550 | 24,505 (0%) | 0% | 50.9 | 129,770 | Common Stock |
| Ultragenyx Pharmaceutical ... | Matthew K. Fust | Director | Sale of securities on an exchange or to another person at price $ 50.85 per share. | 07 Mar 2024 | 2,145 | 22,360 (0%) | 0% | 50.8 | 109,073 | Common Stock |
| Crinetics Pharmaceuticals Inc | Matthew K. Fust | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2023 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | |
| Crinetics Pharmaceuticals Inc | Matthew K. Fust | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2023 | 6,000 | 18,536 (0%) | 0% | 0 | Common Stock | |
| Ultragenyx Pharmaceutical ... | Matthew K. Fust | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 7,110 | 7,110 | - | - | Stock Option (Right to Buy) | |
| Ultragenyx Pharmaceutical ... | Matthew K. Fust | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 3,860 | 30,355 (0%) | 0% | 0 | Common Stock | |
| Ultragenyx Pharmaceutical ... | Matthew K. Fust | Director | Sale or transfer of securities back to the company at price $ 51.82 per share. | 07 Jun 2023 | 3,300 | 27,055 (0%) | 0% | 51.8 | 171,006 | Common Stock |
| Atara Biotherapeutics Inc | Matthew K. Fust | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2023 | 79,500 | 79,500 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Atara Biotherapeutics Inc | Matthew K. Fust | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2023 | 57,000 | 109,000 (0%) | 0% | 0 | Common Stock | |
| Crinetics Pharmaceuticals Inc | Matthew K. Fust | Director | Sale of securities on an exchange or to another person at price $ 20.96 per share. | 13 Jul 2022 | 5,700 | 12,536 (0%) | 0% | 21.0 | 119,455 | Common Stock |
| Crinetics Pharmaceuticals Inc | Matthew K. Fust | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jul 2022 | 5,700 | 0 | - | - | Non-qualified stock option (Right to Buy) | |
| Crinetics Pharmaceuticals Inc | Matthew K. Fust | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.45 per share. | 13 Jul 2022 | 5,700 | 18,236 (0%) | 0% | 1.5 | 8,265 | Common Stock |
| Ultragenyx Pharmaceutical ... | Matthew K. Fust | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2022 | 6,245 | 6,245 | - | - | Stock Option (Right to Buy) | |
| Ultragenyx Pharmaceutical ... | Matthew K. Fust | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2022 | 3,300 | 26,495 (0%) | 0% | 0 | Common Stock | |
| Atara Biotherapeutics Inc | Matthew K. Fust | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2022 | 31,500 | 31,500 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Atara Biotherapeutics Inc | Matthew K. Fust | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2022 | 20,500 | 52,000 (0%) | 0% | 0 | Common Stock | |
| Crinetics Pharmaceuticals Inc | Matthew K. Fust | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2022 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | |
| Ultragenyx Pharmaceutical ... | Matthew K. Fust | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 40.37 per share. | 04 Mar 2022 | 7,500 | 23,195 (0%) | 0% | 40.4 | 302,775 | Common Stock |
| Ultragenyx Pharmaceutical ... | Matthew K. Fust | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2022 | 7,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Atara Biotherapeutics Inc | Matthew K. Fust | Director | Sale of securities on an exchange or to another person at price $ 19.50 per share. | 04 Nov 2021 | 13,354 | 31,500 (0%) | 0% | 19.5 | 260,403 | Common Stock |
| Crinetics Pharmaceuticals Inc | Matthew K. Fust | Director | Sale of securities on an exchange or to another person at price $ 25.50 per share. | 01 Nov 2021 | 8,954 | 12,536 (0%) | 0% | 25.5 | 228,327 | Common Stock |
| Crinetics Pharmaceuticals Inc | Matthew K. Fust | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.91 per share. | 01 Nov 2021 | 8,954 | 21,490 (0%) | 0% | 1.9 | 17,102 | Common Stock |
| Crinetics Pharmaceuticals Inc | Matthew K. Fust | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2021 | 8,954 | 12,092 | - | - | Non-qualified stock option (Right to Buy) | |
| Crinetics Pharmaceuticals Inc | Matthew K. Fust | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.91 per share. | 08 Sep 2021 | 6,046 | 18,582 (0%) | 0% | 1.9 | 11,548 | Common Stock |
| Crinetics Pharmaceuticals Inc | Matthew K. Fust | Director | Sale of securities on an exchange or to another person at price $ 25.50 per share. | 08 Sep 2021 | 6,046 | 12,536 (0%) | 0% | 25.5 | 154,173 | Common Stock |
| Crinetics Pharmaceuticals Inc | Matthew K. Fust | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Sep 2021 | 6,046 | 21,046 | - | - | Non-qualified stock option (Right to Buy) | |
| Crinetics Pharmaceuticals Inc | Matthew K. Fust | Director | Sale of securities on an exchange or to another person at price $ 19.59 per share. | 26 Jul 2021 | 5,000 | 12,536 (0%) | 0% | 19.6 | 97,950 | Common Stock |
| Crinetics Pharmaceuticals Inc | Matthew K. Fust | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jul 2021 | 5,000 | 27,092 | - | - | Non-qualified stock option (Right to Buy) | |
| Crinetics Pharmaceuticals Inc | Matthew K. Fust | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.91 per share. | 26 Jul 2021 | 5,000 | 17,536 (0%) | 0% | 1.9 | 9,550 | Common Stock |
| Crinetics Pharmaceuticals Inc | Matthew K. Fust | Director | Sale of securities on an exchange or to another person at price $ 19.50 per share. | 19 Jul 2021 | 5,000 | 12,536 (0%) | 0% | 19.5 | 97,500 | Common Stock |
| Crinetics Pharmaceuticals Inc | Matthew K. Fust | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jul 2021 | 5,000 | 32,092 | - | - | Non-qualified stock option (Right to Buy) | |
| Crinetics Pharmaceuticals Inc | Matthew K. Fust | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.91 per share. | 19 Jul 2021 | 5,000 | 17,536 (0%) | 0% | 1.9 | 9,550 | Common Stock |
| Crinetics Pharmaceuticals Inc | Matthew K. Fust | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jul 2021 | 5,000 | 37,092 | - | - | Non-qualified stock option (Right to Buy) | |
| Crinetics Pharmaceuticals Inc | Matthew K. Fust | Director | Sale of securities on an exchange or to another person at price $ 20.71 per share. | 12 Jul 2021 | 5,000 | 12,536 (0%) | 0% | 20.7 | 103,550 | Common Stock |
| Crinetics Pharmaceuticals Inc | Matthew K. Fust | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.91 per share. | 12 Jul 2021 | 5,000 | 17,536 (0%) | 0% | 1.9 | 9,550 | Common Stock |
| Ultragenyx Pharmaceutical ... | Matthew K. Fust | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2021 | 4,125 | 4,125 | - | - | Stock Option (Right to Buy) | |
| Ultragenyx Pharmaceutical ... | Matthew K. Fust | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2021 | 2,145 | 15,695 (0%) | 0% | 0 | Common Stock | |
| Crinetics Pharmaceuticals Inc | Matthew K. Fust | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2021 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | |
| Atara Biotherapeutics Inc | Matthew K. Fust | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2021 | 17,500 | 17,500 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Atara Biotherapeutics Inc | Matthew K. Fust | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2021 | 11,000 | 44,854 (0%) | 0% | 0 | Common Stock | |
| Ultragenyx Pharmaceutical ... | Matthew K. Fust | Director | Sale of securities on an exchange or to another person at price $ 90.00 per share. | 06 Jul 2020 | 6,181 | 13,550 (0%) | 0% | 90 | 556,290 | Common Stock |
| Ultragenyx Pharmaceutical ... | Matthew K. Fust | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.00 per share. | 06 Jul 2020 | 6,181 | 19,731 (0%) | 0% | 21 | 129,801 | Common Stock |
| Ultragenyx Pharmaceutical ... | Matthew K. Fust | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jul 2020 | 6,181 | 0 | - | - | Stock Option (Right to Buy) | |
| Ultragenyx Pharmaceutical ... | Matthew K. Fust | Director | Sale of securities on an exchange or to another person at price $ 85.00 per share. | 01 Jul 2020 | 5,000 | 13,550 (0%) | 0% | 85 | 425,000 | Common Stock |
| Ultragenyx Pharmaceutical ... | Matthew K. Fust | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jul 2020 | 5,000 | 6,181 | - | - | Stock Option (Right to Buy) | |
| Ultragenyx Pharmaceutical ... | Matthew K. Fust | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.00 per share. | 01 Jul 2020 | 5,000 | 18,550 (0%) | 0% | 21 | 105,000 | Common Stock |
| Ultragenyx Pharmaceutical ... | Matthew K. Fust | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2020 | 4,250 | 4,250 | - | - | Stock Option (Right to Buy) | |
| Ultragenyx Pharmaceutical ... | Matthew K. Fust | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2020 | 2,550 | 13,550 (0%) | 0% | 0 | Common Stock | |
| Crinetics Pharmaceuticals Inc | Matthew K. Fust | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jun 2020 | 12,500 | 12,500 | - | - | Stock Option (right to buy) | |
| Atara Biotherapeutics Inc | Matthew K. Fust | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2020 | 24,500 | 24,500 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Atara Biotherapeutics Inc | Matthew K. Fust | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2020 | 8,000 | 33,854 (0%) | 0% | 0 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges